Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States
From the perspective of U.S. payers, durvalumab combined with neoadjuvant chemotherapy is a cost-effective strategy compared to chemotherapy alone for treating operable MIBC.
Authors
- Maobai Liu (ORCID: https://orcid.org/0000-0002-8382-7868)
- Bin Zheng (ORCID: https://orcid.org/0000-0002-7682-6648)
- Hongfu Cai (ORCID: https://orcid.org/0000-0002-4923-4882)
- Na Li (ORCID: https://orcid.org/0009-0001-9511-2384)
- Jiahao Zhang (ORCID: https://orcid.org/0000-0001-8456-3756)
- Jianying Lei (ORCID: https://orcid.org/0009-0005-0178-9853)
- Wu Fu
- Caicong You
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251357519
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- National Natural Science Foundation of China